ArticleNeuroepidemiology2026
Increasing Incidence of Guillain-Barré Syndrome in the USA among Integrated Delivery Systems from 2017 to 2023: Trends by Age and Charlson Comorbidity Index Score.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGuillain-Barré syndrome (GBS) is a heterogeneous and rapidly progressive immune-mediated neurologic condition. Recent national estimates of GBS epidemiology are lacking. This real-world study describes GBS incidence trends in the USA from 2017 to 2023.
methodsThis was an observational, retrospective, descriptive, US-based cohort study among adults who had ≥12 months of activity within integrated delivery systems of the US-based Optum's de-identified Market Clarity data (Optum® Market Clarity), which links electronic health records and claims. The primary GBS case definition was an International Classification of Diseases, Tenth Revision, Clinical Modification G61.0 code associated with an inpatient visit.
resultsYearly GBS incidence in adults ranged from 3.1/100,000 person-years (PY) in 2017 to 6.4/100,000 PY in 2023. In the descriptive stratified analyses, GBS incidence was higher among individuals ≥60 years old (4.0-7.3/100,000 PY) than among those <60 years of age (2.6-5.7/100,000 PY) and among those with Charlson Comorbidity Index (CCI) scores ≥2 (6.5-9.7/100,000 PY) compared with those with CCI scores <2 (2.6-5.6/100,000 PY). More than half of GBS patients had acute respiratory illness within 42 days before GBS diagnosis and approximately 60% had chronic medical conditions that predisposed them to severe illness from respiratory viruses. Of note, across all analyses, the yearly number of Optum® Market Clarity subjects decreased over the study period from 37.4 million in 2017 and 3.8 million in 2023, resulting in a reduced eligible denominator for identifying GBS patients.
conclusionThis descriptive analysis reports changing epidemiology of GBS in the USA, where incidence rates may be increasing over time, and individuals with underlying comorbidities and previous infection had higher incidence of GBS. These findings help the current understanding of US GBS epidemiology, which is important for identifying individuals at risk and may contribute to improved patient outcomes through timely diagnosis and management. However, these findings should be interpreted with caution given the descriptive nature of the analysis and the absence of formal statistical testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.